| As of Tuesday's close, MDCX had 6 analyst targets pointing to a significant amount of upside potential.
In fact, with an average target of $23.50, MDCX could have over 3,800% potential upside from its closing valuation on Tuesday the 17th.
MarketBeat reports further that Jason Kolbert of D. Boral Capital has given MDCX a $27 target representing a potential upside over 4,400% from Tuesday's close.
Additionally, the website shares Jason McCarthy of Maxim Group has provided a $20 target suggesting 3,200+% potential upside from Tuesday's close.
Could (Nasdaq: MDCX) be undervalued from current chart levels? -----
No. 4 MDCX Potential Catalyst - The Company Received Critical FDA Clearance For An Important Phase 2b Study.
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse prevention (AURr) collectively representing ~US$6Bn in potential market opp.
PHILADELPHIA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has received “study may proceed” clearance from the U.S. Food and Drug Administration (FDA) to initiate its Phase 2b dose-optimization study of Teverelix®, an investigational next generation long-acting GnRH antagonist, in men with advanced prostate cancer (APC).
...
“Teverelix Phase 2 dose optimization study in advanced prostate cancer represents an important transition point for the Teverelix program,” stated Dr. Raza Bokhari, Medicus Exec. Chairman & CEO. “Our development strategy is intentionally focused on a population that remains underserved by existing therapies. If successful, we believe Teverelix has the potential to become a best-in-class GnRH antagonist and the first hormone therapy specifically supported by a Cardiovascular-risk–focused label in this setting.”
...
Read the full article here. -----
No. 5 MDCX Potential Catalyst - Multiple Technical Indicators Point To This Profile Trending Around Oversold Levels (Healthy Reversal Nearing?).
At 2:00PM EST Tuesday, Barchart was reporting MDCX to have multiple oversold leaning technical indicators.
These technicals could be signaling a healthy reversal is approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Here's the technicals to pay close attention to (as of 2:00PM EST Tuesday):
- 9-Day Relative Strength Index: 30.09%
- 14-Day Relative Strength Index: 31.92%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 9-Day Raw Stochastic %D: 17.70%
- 14-Day Raw Stochastic %D: 10.25%
As the Raw Stochastic nears the 10% range and lower it may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely. -----
(Nasdaq: MDCX) Recap - These 5 Potential Breakout Catalysts Lead The Way
No. 1 - A Low Float Could Create The Environment For Heightened Volatility.
No. 2 - The Company Reported Positive Topline Data On A Key Phase 2 Study.
No. 3 - An Average Of 6 Analyst Targets Suggest Major Potential Upside (Quadruple-Digit).
No. 4 - The Company Received Critical FDA Clearance For An Important Phase 2b Study.
No. 5 - Multiple Technical Indicators Point To This Profile Trending Around Oversold Levels (Healthy Reversal Nearing?). -----
Medicus Pharma Ltd. (Nasdaq: MDCX) tops Wednesday's watchlist.
Be ready for updates coming your way shortly. Talk soon.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/18/2026 and ending on 03/18/2026 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred twenty seven thousand five hundred USD ("Funds"). These Funds were part of the one hundred twenty thousand USD funds that TD Media LLC received from a third party named RazorPitch Inc. who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (MDCX:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/mdcx-2jet8/#details | 
Tidak ada komentar:
Posting Komentar